$ENDP Somewhat Positive News Coverage Somewhat Unl

$ENDP Somewhat Positive News Coverage Somewhat Unlikely to Impact Endo International (ENDP) Share Price




Press coverage about Endo International (NASDAQ:ENDP) (TSE:ENL) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Endo International earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.4323951658065 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have effected Accern’s rankings:

Paladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring (finance.yahoo.com)
Are Earnings Prospects Improving For Loss-Making Endo International plc’s (NASDAQ:ENDP)? (finance.yahoo.com)
Leerink Swann Analysts Increase Earnings Estimates for Endo International plc (ENDP) (americanbankingnews.com)
Endo Receives Paragraph IV Notification on Vasostrict (finanznachrichten.de)
Endo Receives Paragraph IV Notification on Vasostrict® (finance.yahoo.com)
Shares of ENDP opened at $5.74 on Thursday. The stock has a market cap of $1,241.77, a PE ratio of 1.49 and a beta of 0.38. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.02 and a quick ratio of 0.85. Endo International has a 52 week low of $5.27 and a 52 week high of $14.15.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.77 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.15. The business had revenue of $768.64 million during the quarter, compared to analyst estimates of $762.29 million. Endo International had a negative net margin of 58.68% and a positive return on equity of 81.03%. The firm’s revenue for the quarter was down 38.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.77 earnings per share. equities analysts predict that Endo International will post 2.33 EPS for the current year.

A number of research firms have weighed in on ENDP. BidaskClub lowered shares of Endo International from a “sell” rating to a “strong sell” rating in a research report on Friday, April 6th. Canaccord Genuity set a $7.00 target price on shares of Endo International and gave the stock a “hold” rating in a research report on Wednesday, February 21st. Oppenheimer reissued a “hold” rating on shares of Endo International in a research report on Tuesday, February 27th. Barclays set a $9.00 target price on shares of Endo International and gave the stock a “hold” rating in a research report on Saturday, March 10th. Finally, Mizuho lowered shares of Endo International from a “buy” rating to a “neutral” rating and cut their target price for the stock from $12.00 to $7.00 in a research report on Wednesday, April 4th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Endo International currently has an average rating of “Hold” and a consensus price target of $9.40.

WARNING: This news story was originally published by [[site]] and is owned by of [[site]]. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at [[permalink]].
About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.



The views expressed in any and all content distributed by Newstex and its re-distributors (collectively, the "Newstex Authoritative Content" are solely those of the respective author(s) and not necessarily the views of Newstex or its re-distributors. Stories from such authors are provided "AS IS," with no warranties, and confer no rights. The material and information provided in Newstex Authoritative Content are for general information only and should not, in any respect, be relied on as professional advice. Newstex Authoritative Content is not "read and approved" before it is posted. Accordingly, neither Newstex nor its re-distributors make any claims, promises or guarantees about the accuracy, completeness, or adequacy of the information contained therein or linked to from such content, nor do they take responsibility for any aspect of such content. The Newstex Authoritative Content shall be construed as author-based content and commentary. Accordingly, no warranties or other guarantees are offered as to the quality of the opinions, commentary or anything else appearing in such Newstex Authoritative Content. Newstex and its re-distributors expressly reserve the right to delete stories at its and their sole discretion.


Source: Online Publications (April 19, 2018 - 10:42 AM EDT)

News by QuoteMedia
www.quotemedia.com